A novel botulinum neurotoxin topical gel: Treatment of allergic rhinitis in rats and comparative safety profile

American Journal of Rhinology and Allergy

Volumn 26, Issue 6, 2012, Pages 450-454

  Zhu, Zhao ^a   Stone, Hongran F ^a   Thach, Thai Q D ^a   Garcia, Luke ^a   Ruegg, Curtis L ^a  

^a Revance Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; RT 001; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ALLERGIC RHINITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SAFETY; EDEMA; FEMALE; GUINEA PIG; LETHALITY; NASAL PRURITUS; NONHUMAN; NOSE OBSTRUCTION; PROTEIN EXPRESSION; RAT; SNEEZING; THERAPY EFFECT; WEIGHT GAIN;

ADMINISTRATION, TOPICAL; ANIMALS; BOTULINUM TOXINS, TYPE A; FEMALE; GELS; GUINEA PIGS; IMMUNOHISTOCHEMISTRY; RATS; RATS, SPRAGUE-DAWLEY; RHINITIS, ALLERGIC, PERENNIAL;

EID: 84871046653     PISSN: 19458924     EISSN: 19458932     Source Type: Journal    
DOI: 10.2500/ajra.2012.26.3785     Document Type: Article

References (34)

1. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: An updated practice parameter. J Allergy Clin Immunol 122:S1-S84, 2008. (Erratum in J Allergy Clin Immunol 122:1237, 2008.) (Pubitemid 352033573)
2. Brozek JL, Bousquet J, Baena-Cagnani CE, et al. J Allergy Clin Immunol 126:466-476, 2010.
3. Blasi J, Chapman ER, Link E, et al. Botulinum neurotoxin A selectively cleaves the synaptic NOT protein SNAP-25. Nature 365:160-163,1993. (Pubitemid 23282061)
4. Turton K, Chaddock JA, and Acharya KR. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem Sci 27:552-558, 2002. (Pubitemid 35335403)
5. Jankovic J. Botulinum toxin in movement disorders. Curr Opin Neurol 7:358-366, 1994. (Pubitemid 24243742)
6. Brin MF. Botulinum toxin: Chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl 6:S146-S168, 1997.
7. Koman LA, Mooney JF II, Smith BP, et al. Management of spasticity in cerebral palsy with botulinum-A toxin: Report of a preliminary, randomized, double-blind trial. J Pediatr Orthop 14:299-303, 1994. (Pubitemid 24129823)
8. Cheng CM, Chen JS, and Patel RP. Unlabeled uses of botulinum toxins: A review, part 1. Am J Health Syst Pharm 63:145-152, 2006. (Pubitemid 43100360)
9. Cheng CM, Chen JS, and Patel RP. Unlabeled uses of botulinum toxins: A review, part 2. Am J Health Syst Pharm 63:225-232, 2006. (Pubitemid 43165374)
10. Lowe NJ. Overview of botulinum neurotoxins. J Cosmet Laser Ther 9(suppl 1):11-16, 2007. (Pubitemid 47450880)
11. Flynn TC. Update on botulinum toxin. Semin Cutan Med Surg 26: 196-202, 2007. (Pubitemid 351459648)
12. Klein AW, Carruthers A, Fagien S, et al. Comparisons among botulinum toxins: An evidence-based review. Plast Reconstr Surg 121: 413e-422e, 2008.
13. Brandt F, O'Connell C, Cazzaniga A, et al. Efficacy and safety evaluation of a novel botulinum toxin topical gel for the treatment of moderate to severe lateral canthal lines. Dermatol Surg 36:2111-2118, 2010.
14. Laing TA, Laing ME, and O'Sullivan ST. Botulinum toxin for treatment of glandular hypersecretory disorders. J Plast Reconstr Aesthet Surg 61:1024-1028, 2008.
15. Shaari CM, Sanders I, Wu BL, et al. Rhinorrhea is decreased in dogs after nasal application of botulinum toxin. Otolaryngol Head Neck Surg 112:566-571, 1995.
16. Lung MA. M1 and M3 muscarinic receptors mediate relaxation and contraction of canine nasal veins. Am J Rhinol Allergy 25:e60-e65, 2011.
17. Rohrbach S, Olthoff A, Laskawi R, et al. Botulinum toxin type A induces apoptosis in nasal glands of guinea pigs. Ann Otol Rhinol Laryngol 110:1045-1050, 2001. (Pubitemid 33049405)
18. Wen WD, Yuan F, Wang JL, et al. Botulinum toxin therapy in the ovalbumin-sensitized rat. Neuroimmunomodulation 14:78-83, 2007. (Pubitemid 47442985)
19. Kim KS, Kim SS, Yoon JH, et al. The effect of botulinum toxin type A injection for intrinsic rhinitis. J Laryngol Otol 112:248-251, 1998.
20. Rohrbach S, Laskawi R. Minimally invasive application of botulinum toxin type A in nasal hypersecretion. ORL J Otorhinolaryngol Relat Spec 63:382-384, 2001. (Pubitemid 33079295)
21. Unal M, Sevim S, Doǧu O, et al. Effect of botulinum toxin type A on nasal symptoms in patients with allergic rhinitis: A double-blind, placebo-controlled clinical trial. Acta Otolaryngol 123:1060-1063, 2003. (Pubitemid 38021522)
22. Ozcan C, Vayisoglu Y, Doǧu O, et al. The effect of intranasal injection of botulinum toxin A on the symptoms of vasomotor rhinitis. Am J Otolaryngol 27:314-318, 2006. (Pubitemid 44278337)
23. Yang TY, Jung YG, Kim YH, et al. A comparison of the effects of botulinum toxin A and steroid injection on nasal allergy. Otolaryngol Head Neck Surg 139:367-371, 2008.
24. Sapci T, Yazici S, Evcimik MF, et al. Investigation of the effects of intranasal botulinum toxin type A and ipratropium bromide nasal spray on nasal hypersecretion in idiopathic rhinitis without eosinophilia. Rhinology 46:45-51, 2008.
25. Rohrbach S, Junghans K, Köhler S, et al. Minimally invasive application of botulinum toxin A in patients with idiopathic rhinitis. Head Face Med 5:18, 2009.
26. Sugimoto Y, Ishizawa K, Saitou K, et al. Effect of mometasone furoate by topical application on allergic rhinitis model in rats. Pharmacology 61:91-95, 2000. (Pubitemid 30665988)
27. Wilhelm CM. Oral LD50 of botulinum toxin serotype A in guinea pigs. MS thesis submitted in partial fulfillment of the requirements for the degree of Master of Science, Wright State University, 1-62, 2007.
28. Heppt W, Peiser C, Cryer A, et al. Innervation of human nasal mucosa in environmentally triggered hyperreflectoric rhinitis. J Occup Environ Med 44:924-929, 2002.
29. Korsgren M, Erjefält JS, Hinterholzl J, et al. Neural expression and increased lavage fluid levels of secretoneurin in seasonal allergic rhinitis. Am J Respir Crit Care Med 167:1504-1508, 2003. (Pubitemid 37363359)
30. Fischer A, Wussow A, Cryer A, et al. Neuronal plasticity in persistent perennial allergic rhinitis. J Occup Environ Med 47:20-25, 2005. (Pubitemid 40129009)
31. Bellamy JL, Cady RK, and Durham PL. Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients. Headache 46:24-33, 2006.
32. Fang SY, and Shen CL. Neuropeptide innervation and neuroendocrine cells in allergic rhinitis and chronic hypertrophic rhinitis. Clin Exp Allergy 28:228-232, 1998.
33. Cheng LW, Onisko B, Johnson EA, et al. Effects of purification on the bioavailability of botulinum neurotoxin type A. Toxicon 249:123-129, 2008.
34. Stone HF, Zhu Z, Thach TQD, et al. Characterization of diffusion and duration of action of a new botulinum neurotoxin type A formulation. Toxicon 58:159-167, 2011.